HIV molecular immunology database
Found 1 matching record:
HXB2 Location | Pol(330-338) | Pol Epitope Map
View variants at this location |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Epitope |
NPEIVIYQY
|
Epitope Alignment | ||||||||||
Variants |
|
|||||||||||
Epitope Name | NY9 | |||||||||||
Species (MHC/HLA) | human(B*35:01) |
Showing all: 3 variant(s).
Variant ID. | 3962 |
---|---|
Epitope Seq. | NPEIVIYQY |
Variant Seq. | NPEIVIiQY |
Mutations | Y/I |
Epitope Location | Y7I |
HXB2 Location | Y336I |
Mutation Type | DR: diminished response SF: susceptible form |
Epitope Subtype | CRF01_AE |
Variant Subtype | CRF01_AE |
Method | CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining |
Note | Subtype A/E's NY9-3E mutant, NY9-3E7I, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7I peptide as well as they did WT NY9-3E, but KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7I. NY9-3E-specific CTL from KI-805 recognized NY9-3E7I peptide more strongly than WT but 7I-infected cells were recognized similarly to WT. Affinity of NY9-3E7I was greater for HLA-B*3501 when compared to WT NY9-3E. |
Variant ID. | 3963 |
---|---|
Epitope Seq. | NPEIVIYQY |
Variant Seq. | NPEIVIvQY |
Mutations | Y/V |
Epitope Location | Y7V |
HXB2 Location | Y336V |
Mutation Type | DR: diminished response SF: susceptible form |
Epitope Subtype | CRF01_AE |
Variant Subtype | CRF01_AE |
Method | CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining |
Note | Subtype A/E's NY9-3E mutant, NY9-3E7V, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7V peptide more weakly than WT NY9-3E, and KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7V. NY9-3E-specific CTL from KI-805 recognized NY9-3E7V peptide as well as 7V-infected cells more strongly than WT . Affinity of NY9-3E7V was greater for HLA-B*3501 when compared to WT NY9-3E. |
Variant ID. | 3964 |
---|---|
Epitope Seq. | NPEIVIYQY |
Variant Seq. | NPEIVIcQY |
Mutations | Y/C |
Epitope Location | Y7C |
HXB2 Location | Y336C |
Mutation Type | DR: diminished response SF: susceptible form |
Epitope Subtype | CRF01_AE |
Variant Subtype | CRF01_AE |
Method | CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining |
Note | Subtype A/E's NY9-3E mutant, NY9-3E7C, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7C peptide more weakly than WT NY9-3E, and KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7C. NY9-3E-specific CTL from KI-805 recognized NY9-3E7C peptide as well as 7C-infected cells more weakly than WT . Affinity of NY9-3E7C was greater for HLA-B*3501 when compared to WT NY9-3E. |
Kuse2015 Nozomi Kuse, Mohammad Arif Rahman, Hayato Murakoshi, Giang Van Tran, Takayuki Chikata, Madoka Koyanagi, Kinh Van Nguyen, Hiroyuki Gatanaga, Shinichi Oka, and Masafumi Takiguchi. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections. J. Virol., 89(14):7363-7372, Jul 2015. PubMed ID: 25972553. Show all entries for this paper.